1,487 results on '"Califf RM"'
Search Results
2. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
3. INFLUENCES ON SERIOUSLY ILL PATIENTS' MEDICAL DECISIONS
4. ACUTE EXACERBATION OF SEVERE HEART FAILURE: HOSPITAL AND LONG TERM OUTCOMES
5. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
6. Rivaroxaban compared with warfarin in patients with atrial fibrillation and prior stroke or transient ischaemic attack: a prespecified subgroup analysis of the ROCKET AF trial
7. Geographic Variation in Clinical Course Among Patients Hospitalized for Acute Heart Failure: Insights From ASCEND-HF
8. Baseline Cystatin C is Associated with Short-Term Adverse Events in Acute Heart Failure but Does Not Predict Treatment Effects with Nesiritide Therapy
9. High Sensitivity Troponin I in Acute Decompensated Heart Failure: Insights from the ASCEND-HF Study
10. Mortality and morbidity remain high despite captopril and/or valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction - Results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT)
11. Case Study for Lean Management in the Public Sector: Improving Combination Product Review at the Food & Drug Administration.
12. Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R2CHADS2 Index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) Study Cohorts.
13. Evaluating the impact of public health notification: duke clopidogrel experience.
14. Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study.
15. Regional patterns of use of a medical management strategy for patients with non-ST-segment elevation acute coronary syndromes: insights from the EARLY ACS Trial.
16. Relationship between vein graft failure and subsequent clinical outcomes after coronary artery bypass surgery.
17. American industry and the u.s. Cardiovascular clinical research enterprise an appropriate analogy?
18. The STARBRITE Trial: A Randomized, Pilot Study of B-Type Natriuretic Peptide-Guided Therapy in Patients With Advanced Heart Failure.
19. Saphenous vein grafts with multiple versus single distal targets in patients undergoing coronary artery bypass surgery: one-year graft failure and five-year outcomes from the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV trial.
20. Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials.
21. Refining clinical trial composite outcomes: An application to the Assessment of the Safety and Efficacy of a New Thrombolytic-3 (ASSENT-3) trial.
22. Cardiovascular research in India: A perspective.
23. Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial.
24. Prior cardiovascular interventions are not associated with worsened clinical outcomes in patients with symptomatic atherothrombosis.
25. Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT)
26. ST2 and mortality in non-ST-segment elevation acute coronary syndrome.
27. Mechanical dyssynchrony after myocardial infarction in patients with left ventricular dysfunction, heart failure, or both.
28. Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry.
29. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial)
30. Long-term mortality of patients undergoing cardiac catheterization for ST-elevation and non-ST-elevation myocardial infarction.
31. Careers for clinician investigators.
32. Relation between aspirin dose, all-cause mortality, and bleeding in patients with recent cerebrovascular or coronary ischemic events (from the BRAVO Trial)
33. Initial aspirin dose and outcome among ST-elevation myocardial infarction patients treated with fibrinolytic therapy.
34. Time to coronary angiography and outcomes among patients with high-risk non-ST-segment-elevation acute coronary syndromes: results from the SYNERGY trial.
35. Clinical outcomes of palliative surgery including a systemic-to-pulmonary artery shunt in infants with cyanotic congenital heart disease: does aspirin make a difference?
36. Impact of initial heart rate and systolic blood pressure on relation of age and mortality among fibrinolytic-treated patients with acute ST-elevation, myocardial infarction presenting with cardiogenic shock.
37. Economic return of clinical trials performed under the pediatric exclusivity program.
38. Late ischemic events after clopidogrel cessation following drug-eluting stenting: should we be worried?
39. How changes in drug-safety regulations affect the way drug and biotech companies invest in innovation: Expanded Phase III clinical testing will affect these decisions more than increased postmarketing safety efforts will.
40. Assessment and treatment of depression in patients with cardiovascular disease: national heart, lung, and blood institute working group report.
41. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial.
42. Statin use and sex-specific stroke outcomes in patients with vascular disease.
43. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease.
44. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.
45. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study.
46. AHA scientific statement: practice standards for electrocardiographic monitoring in hospital settings: an American Heart Association Scientific Statement from the Councils on Cardiovascular Nursing, Clinical Cardiology, and Cardiovascular Disease in...
47. High-dose statins in acute coronary syndromes.
48. Lessons learned from a clinical trial.
49. Prognostic value of anxiety and depression in patients with chronic heart failure.
50. Practice standards for electrocardiographic monitoring in hospital settings: an American Heart Association Scientific Statement from the Councils on Cardiovascular Nursing, Clinical Cardiology, and Cardiovascular Disease in the Young.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.